The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B
Open accessAbstract
BACKGROUND: We describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil, or FIAU) as therapy for chronic hepatitis B virus infection. METHODS: Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks and were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. RESULTS: During the 13th week lactic acidosis and liver failure suddenly developed in one patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function despite the discontinuation of fialuridine. Three other patients had mild hepatotoxicity. Several patients also had pancreatitis, neuropathy, or myopathy. Of the seven patients with severe hepatotoxicity, five died and two survived after liver transplantation. Histologic analysis of liver tissue revealed marked accumulation of microvesicular and macrovesicular fat, with minimal necrosis of hepatocytes or architectural changes. Electron microscopy showed abnormal mitochondria and the accumulation of fat in hepatocytes. CONCLUSIONS: In patients with chronic hepatitis B, treatment with fialuridine induced a severe toxic reaction characterized by hepatic failure, lactic acidosis, pancreatitis, neuropathy, and myopathy. This toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine, an antiviral nucleoside analogue, caused catastrophic hepatic failure and lactic acidosis in a 1993 clinical trial, resulting in five deaths and two liver transplantations.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies across multiple species showed no indication of the severe mitochondrial toxicity observed in humans, because fialuridine’s incorporation into mitochondrial DNA is mediated by a human-specific mitochondrial transporter [69,70].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Even a pilot study on 43 patients treated for 2 and 4 weeks duration with Fialuridine did not reveal any signs of hepatic toxicity on initial examination.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“During 13th week of phase II studies, one of the patients suddenly developed hepatic toxicity and lactic acidosis. At this point, trial was stopped for all other patients.”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Even after discontinuation of Fialuridine administration, seven other patients showed signs of severe hepatic toxicity five of which could not survive and other two could survive only after liver transplantation.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, D., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 974
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K. L., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C. H., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 838
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B. H., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 837
Doong, S.-L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., & Cheng, Y. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8495 · Cited by 513
Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
Arnaudo, E., Shanske, S., DiMauro, S., Schon, E. A., Moraes, C. T., Schon, E. A., & Dalakas, M. C. (1991) · The Lancet · doi:10.1016/0140-6736(91)91294-5 · Cited by 504
Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B
Hoofnagle, J. H., Peters, M. G., Mullen, K. D., Jones, D. B., Rustgi, V. K., Bisceglie, A. M. D., Hallahan, C. W., Park, Y., Meschievitz, C., & Jones, E. A. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90367-8 · Cited by 420
Self-citationReversal of Fulminant Hepatic Failure Using An Extracorporeal Liver Assist Device
Sussman, N., Chong, M. G., Koussayer, T., He, D.-E., Shang, T. A., Whisennand, H. H., & Kelly, J. H. (1992) · Hepatology · doi:10.1002/hep.1840160112 · Cited by 341
Chen, C., Vazquez-Padua, M. A., & Cheng, Y. C. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11067-5 · Cited by 296
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Lok, A. S.-F., Wu, P., Lai, C., Lau, J. Y. N., Leung, E. K. Y., Wong, L. S. K., Ma, O. C. K., Lauder, I. J., Ng, C. P. L., & Chung, H.-T. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90337-x · Cited by 239
Hodge, R. A. V., Sutton, D., Boyd, M. R., Harnden, M. R., & Jarvest, R. L. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1765 · Cited by 207
Research works printed but not linked: 7
- Dusheiko G, Hoofnagle JH. Hepatitis B. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. New York: Oxford University Press, 1991:571-92.
- Paar DP, Hooten TM, Smiles KA, et al. The effect of FIAU on chronic hepatitis B virus (HBV) infection in HIV-infected subjects (ACTG 122b). In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10–14, 1992. Washington, D.C.: American Society for Microbiology, 1992:264. abstract.
- 10.1002/hep.1840160402 · DOI
- Stevenson W, 1995, Transplant Proc, 27, 1219
- Chen CH, 1991, Mol Pharmacol, 39, 625
- Klecker RW, 1994, Mol Pharmacol, 46, 1204
- Maxson CJ, 1992, Am J Gastroenterol, 87, 708
Cited by
Sorted by citations
Items 301–400 of 614
Abo‐zeid, Y., Mantovani, G., Irving, W. L., & Garnett, M. C. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.05.027 · Cited by 26
The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity
Leung, G., & Tse, C. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.5.705 · Cited by 26
Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?
Ballet, F. (2015) · Digestive Diseases · doi:10.1159/000374093 · Cited by 25
Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections
Qu, C., Zhang, S., Li, Y., Wang, Y., Peppelenbosch, M. P., & Pan, Q. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2075 · Cited by 25
Cohen, S. M., Levy, R. M., Jovanovich, J. F., & Ahn, J. C. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31819c3945 · Cited by 25
Sutherland, J. E., Hettinger, J. L., Chan, A., Gilbert, J., Warner, G. L., & Davis, W. P. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0796 · Cited by 25
Nucleoside analogues in the treatment of chronic hepatitis B
Leung, N. W. Y. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02103.x · Cited by 25
Systems pharmacology modeling: an approach to improving drug safety
Bai, J. P. F., Fontana, R. J., Price, N. D., & Sangar, V. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1871 · Cited by 24
Webster, J. D., Santagostino, S. F., & Foreman, O. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03101-y · Cited by 25
A microfluidic thyroid-liver platform to assess chemical safety in humans
Kuehnlenz, J. (2022) · ALTEX · doi:10.14573/altex.2108261 · Cited by 26
Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients
Tak, W. Y., Park, S. Y., Jung, M. K., Jeon, S. W., Cho, C. M., Kweon, Y. O., Kim, S. K., & Choi, Y. H. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00515.x · Cited by 24
The Role of Hepatitis C Virus (HCV) in Mitochondrial Dna Damage in HIV/HCV-Coinfected Individuals
de Mendoza, C., & Soriano, V. (2005) · Antiviral Therapy · doi:10.1177/135965350501002s12 · Cited by 24
Pathophysiology of metabolic acid-base disturbances in patients with critical illness
Magder, S. A. (1998) · Springer eBooks · doi:10.1007/978-94-011-5482-6_24 · Cited by 24
Nucleoside analogues for chronic hepatitis B
Wolters, L. M. M., Niesters, H. G. M., & de Man, R. A. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200112000-00016 · Cited by 24
Replacing, reducing and refining the use of animals in tuberculosis vaccine research
Tanner, R. (2016) · ALTEX · doi:10.14573/altex.1607281 · Cited by 23
DNA polymerase inhibitors for treating hepatitis B: a safety evaluation
Mak, L., Seto, W., Lai, C., & Yuen, M. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1139573 · Cited by 23
Lieveld, F. I., Smit, C., Richter, C., van Erpecum, K. J., Spanier, B. W. M., Gisolf, E. H., Vrolijk, J. M., Siersema, P. D., Hoepelman, A. I. M., Reiss, P., et al. (2018) · Liver International · doi:10.1111/liv.14000 · Cited by 23
Sensitive Assay for Mitochondrial DNA Polymerase γ
Naviaux, R. K., Markusic, D. M., Barshop, B. A., Nyhan, W. L., & Haas, R. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.10.1725 · Cited by 23
Lewis, W. (2004) · Mitochondrion · doi:10.1016/j.mito.2004.05.010 · Cited by 23
Review article: nucleoside analogues for the treatment of chronic hepatitis B
Younger, H. M., Bathgate, A. J., & Hayes, P. C. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02211.x · Cited by 22
Michalak, T. I., Zhang, H., Churchill, N. D., Larsson, T., Johansson, N., & Öberg, B. F. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00263-09 · Cited by 22
XNA enzymes by evolution and design
Malik, T. N., & Chaput, J. C. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100012 · Cited by 22
Brind, A. M., Bennett, M. K., & Bassendine, M. F. (1998) · Liver International · doi:10.1111/j.1600-0676.1998.tb00139.x · Cited by 22
How will we use the new antiviral agents for hepatitis B?
Perrillo, R. P. (2002) · Current Gastroenterology Reports · doi:10.1007/s11894-002-0039-6 · Cited by 22
Mechanisms of Post-critical Illness Cardiovascular Disease
Owen, A., Patel, J. M., Parekh, D., & Bangash, M. N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.854421 · Cited by 22
Utility of human hepatocyte spheroids without feeder cells for evaluation of hepatotoxicity
Ogihara, T., Arakawa, H., Jomura, T., Idota, Y., Koyama, S., Yano, K., & Kojima, H. (2017) · The Journal of Toxicological Sciences · doi:10.2131/jts.42.499 · Cited by 21
In-silico approach for drug induced liver injury prediction: Recent advances
Saini, N., Bakshi, S., & Sharma, S. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.06.1216 · Cited by 21
Birkuš, G., Gibbs, C. S., & Cihlář, T. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00399.x · Cited by 21
Woodman, D. D. (2010) · Taylor & Francis eBooks · doi:10.4324/9780203362563_chapter_6 · Cited by 21
Smee, D. F., & Sidwell, R. W. (2004) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-120028334 · Cited by 21
Lee, L. M., & Henderson, D. K. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200108000-00012 · Cited by 22
Imaging expression of adenoviral HSV1-tk suicide gene transfer using the nucleoside analogue FIRU
Nanda, D., de Jong, M., Vogels, R., Havenga, M. J. E., Driesse, M. J., Bakker, W. H., Bijster, M., Avezaat, C. J. J., Cox, P. H., Morin, K. W., et al. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0839-9 · Cited by 21
Schafer, D. F., & Sorrell, M. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361609 · Cited by 21
Short-interference RNAs: becoming medicines
Martínez, T., Jiménez, A. I., & Pañeda, C. (2015) · EXCLI journal · doi:10.17179/excli2015-297 · Cited by 21
Lactic acidosis during telbivudine treatment for HBV: A case report and literature review
Jin, J. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i33.5575 · Cited by 20
Noto, F. K., Adjan, V. V., Tong, M., Ravichandran, K., Zhang, W., Arey, A., McClain, C. B., Ostertag, E. M., Mazhar, S., Sangodkar, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0156 · Cited by 20
Kamimura, H., & Ito, S. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1091113 · Cited by 19
Severe Lactic Acidosis Associated With Juice of the Mangosteen Fruit Garcinia mangostana
Wong, L. P., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.12.043 · Cited by 19
Interaction of Calf Thymus DNA with the Antiviral Drug Lamivudine
Shahabadi, N., Maghsudi, M., Mahdavi, M., & Pourfoulad, M. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1228 · Cited by 19
DAY, L., Shikuma, C. M., & Gerschenson, M. (2004) · Mitochondrion · doi:10.1016/j.mito.2004.06.011 · Cited by 19
Elevated Lactate Levels in Hospitalized Persons with HIV Infection
Tantisiriwat, W., Tebas, P., Polish, L. B., Casabar, E., Powderly, W. G., & Fichtenbaum, C. J. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/088922201750063106 · Cited by 19
THERAPY WITH NUCLEOSIDE ANALOGUES FOR HEPATITIS B VIRUS INFECTION
Rosenberg, P. M., & Dienstag, J. L. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70072-6 · Cited by 19
Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis
Grellier, L., & Dusheiko, G. M. (1997) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.1997.tb00171.x · Cited by 19
Hau, R. K., Wright, S. H., & Cherrington, N. J. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2984 · Cited by 18
Evaluation of drug-induced injury and human response in precision-cut tissue slices
Vickers, A. E. M., & Fisher, R. L. (2012) · Xenobiotica · doi:10.3109/00498254.2012.732714 · Cited by 18
Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
Vickers, A. E. M., Ulyanov, A. V., & Fisher, R. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030574 · Cited by 18
Mégarbane, B., Brivet, F., Guérin, J.-M., & Baud, F. J. (1999) · PubMed · Cited by 18
Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
Osborn, M. K. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5318 · Cited by 17
Haas, R. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05494.x · Cited by 17
Mitochondrial DNA Impairment in Nucleoside Reverse Transcriptase Inhibitor-Associated Cardiomyopathy
Kohler, J. J., Hosseini, S. H., & Lewis, W. (2008) · Chemical Research in Toxicology · doi:10.1021/tx8000219 · Cited by 16
Leung, G. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_16 · Cited by 16
Morgan, S. J., Couch, J. A., Guzzie‐Peck, P., Keller, D. A., Kemper, R., Otieno, M. A., Schulingkamp, R. J., & Jones, T. W. A. (2017) · Toxicologic Pathology · doi:10.1177/0192623317701004 · Cited by 16
Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd Edition): DNA Viruses
Field, H. J., & Clercq, E. D. (2008) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020801900203 · Cited by 16
Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker®
Brandsma, I., Derr, R. S., Zhang, G., Moelijker, N., Hendriks, G., & Østerlund, T. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.04.002 · Cited by 16
Mohamed, A. K., & Magdy, M. (2017) · Electronic physician · doi:10.19082/4261 · Cited by 16
The role of investigative molecular toxicology in early stage drug development
Gross, C. J., & Kramer, J. A. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.2.147 · Cited by 16
Clercq, E. D., & Field, H. J. (2008) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020801900204 · Cited by 15
Mechanisms of Cell Death and Relevance to Drug Toxicity
Dara, L., Han, D., & Kaplowitz, N. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00006-6 · Cited by 15
Severe Toxicity of Fialuridine (FIAU)
Lewis, W., & Perrino, F. W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341715 · Cited by 15
A liver‐humanized mouse model of carbamoyl phosphate synthetase 1‐deficiency
Srinivasan, R. C., Zabulica, M., Hammarstedt, C., Wu, T., Gramignoli, R., Kannisto, K., Ellis, E. C. S., Karadagi, A., Fingerhut, R., Allegri, G., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12067 · Cited by 14
Utility of human hepatocyte spheroids for evaluation of hepatotoxicity
Ogihara, T., Iwai, H., Inoue, Y., Katagi, J., Matsumoto, N., Motoi-Ohtsuji, M., Kakiki, M., Kaneda, S., Nagao, T., Kusumoto, K., et al. (2015) · Fundamental Toxicological Sciences · doi:10.2131/fts.2.41 · Cited by 14
Targeting Hepatitis B Therapy to the Liver
Rensen, P. C. N., de Vrueh, R. L. A., & van Berkel, T. J. C. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631020-00005 · Cited by 14
Exonuclease Removal of Dideoxycytidine (Zalcitabine) by the Human Mitochondrial DNA Polymerase
Hanes, J. W., & Johnson, K. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00778-07 · Cited by 14
Therapeutic advances in the management of hepatitis B and hepatitis C
Nguyen, M. H., & Wright, T. L. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200110000-00014 · Cited by 14
Current pharmacotherapy for the treatment of chronic hepatitis B
Lagget, M., & Rizzetto, M. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.10.1821 · Cited by 14
Role of liver biopsy in the management of idiosyncratic DILI
Kleiner, D. E. (2024) · Liver International · doi:10.1111/liv.16097 · Cited by 13
Self-citationChallenges and opportunities of translating animal research into human trials in Ethiopia
Abrhaley, A., Giday, M., & Hailu, A. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02338-8 · Cited by 13
Growth and Development of a New Subspecialty: Pediatric Hepatology
Balistreri, W. F. (2013) · Hepatology · doi:10.1002/hep.26580 · Cited by 13
Treatment of Hepatitis C: Don’t Put All Your Eggs in One Basket!
Pawlotsky, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.014 · Cited by 13
Emerging drugs for hepatitis B
Zoulim, F. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.2.199 · Cited by 13
Indinavir alters regulators of protein anabolism and catabolism in skeletal muscle
Hong‐Brown, L. Q., Pruznak, A. M., Frost, R. A., Vary, T. C., & Lang, C. H. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00591.2004 · Cited by 13
Sanyal, A. J., & Stravitz, R. T. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50026-7 · Cited by 13
Tong, Y., Ueyama-Toba, Y., Yokota, J., Matsui, H., Kanai, M., & Mizuguchi, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-61544-y · Cited by 13
TAK-994 mechanistic investigation into drug-induced liver injury
Shinozawa, T., Miyamoto, K., Baker, K. S., Faber, S. C., Flores, R., Uetrecht, J., von Hehn, C., Yukawa, T., Tohyama, K., Kadali, H., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf003 · Cited by 13
Oxygen in mitochondrial disease: can there be too much of a good thing?
Mootha, V. K., & Chinnery, P. F. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0210-3 · Cited by 12
Cloning of mouse mitochondrial thymidine kinase 2 cDNA
Wettin, K., Johansson, M., Zheng, X., Zhu, C., & Karlsson, A. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01325-3 · Cited by 12
Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period
Yu, A. S., & Keeffe, E. B. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00044-8 · Cited by 12
Current pharmacotherapy for hepatitis B infection
Galan, M. V., Gordon, S. C., & Boyce, D. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.8.1289 · Cited by 12
Clinical Trials—Collecting Safety Data and Establishing the Adverse Drug Reactions Profile
Talbot, J. C. C., Keisu, M., & Ståhle, L. (2011) · Wiley eBooks · doi:10.1002/9780470975053.ch4 · Cited by 12
Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety
Jadalannagari, S., & Ewart, L. C. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2328794 · Cited by 11
Biomarkers for drug-induced liver injury
Watkins, P. B. (2010) · Therapy · doi:10.2217/thy.10.10 · Cited by 11
Hepatotoxicity Due to Mitochondrial Injury
Lemasters, J. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00005-4 · Cited by 11
Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities
Atienzar, F., & Nicolas, J.-M. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_7 · Cited by 11
Clinical Analysis of Adverse Drug Reactions
Calis, K. A., Sidawy, E. N., & Young, L. R. D. (2007) · Elsevier eBooks · doi:10.1016/b978-012369417-1/50065-1 · Cited by 11
Clinical Analysis of Adverse Drug Reactions: A Primer for Clinicians
Calis, K. A., & Young, L. R. D. (2004) · Hospital Pharmacy · doi:10.1177/001857870403900712 · Cited by 11
(2005) · Humana Press eBooks · doi:10.1385/1592598323 · Cited by 11
In Vivo Monitoring of Gene Therapy by Radiotracer Imaging
Blasberg, R. G., & Tjuvajev, J. G. (1997) · Springer eBooks · doi:10.1007/978-3-642-60844-5_11 · Cited by 11
ANIMAL MODELS OF HEPATITIS B VIRUS INFECTION
Tennant, B. C. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70067-2 · Cited by 11
Herrero, J. I., Quiroga, J. A., Sangro, B., Sola, I., Riezu‐Boj, J. I., Pardo, F., & Prìeto, J. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018887203545 · Cited by 11
DILI prediction in drug development: present and future
Uetrecht, J. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2495955 · Cited by 10
Jolly, C., Douglas, O., Kamalian, L., Jenkins, R. E., Beckett, A. J., Penman, S. L., Williams, D. P., Monshouwer, M., Simic, D., Snoeys, J., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115163 · Cited by 10
Prieto-Martínez, F. D., Gortari, E. F., Medina‐Franco, J. L., & Espinoza‐Fonseca, L. M. (2021) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2021.100008 · Cited by 10
Zhang, P., Zhang, L., Jiang, Z., Xiong, Y., Chen, H., Tao, Y., Hu, M., & Li, Z. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01520-10 · Cited by 10
The current status of oncolytic viral therapy for head and neck cancer
Old, M. O., Wise-Draper, T. M., Wright, C. L., Kaur, B., & Teknos, T. N. (2016) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1016/j.wjorl.2016.05.009 · Cited by 10
Papadopoulos, K. P., & Sherman, W. H. (2002) · American Journal of Cancer · doi:10.2165/00024669-200201050-00003 · Cited by 10
Nicoll, A., LOCARNINI, S. A., Chou, S. T., Smallwood, R. A., & Angus, P. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02079.x · Cited by 10
Risks and benefits of antiretroviral therapy in HIV–HCV co-infected patients
Núñez, M., & Soriano, V. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.011 · Cited by 10
A Novel Stereoselective Access to Substituted l-2-Deoxypentono-1,4-lactones and l-2-Deoxypentoses
Johnson, D. V., Fischer, R. C., & Griengl, H. (2000) · Tetrahedron · doi:10.1016/s0040-4020(00)00871-1 · Cited by 10
Routledge, P. A. (2003) · Wiley eBooks · doi:10.1002/0470014199.ch2 · Cited by 10
Metadata
- Authors
- McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., Pruett, T., Stotka, J. L., Straus, S. E., & Hoofnagle, J. H.
- Affiliations
- National Institutes of Health (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Cancer Institute (UA)
- University of Virginia Hospital (US)
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-10-26
- Volume
- 333
- Issue
- 17
- Pages
- 1099-1105
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2327070670
- Cited by
- 616
- References
- 39
- Citations by year
- 2026: 14 · 2025: 11 · 2024: 17 · 2023: 13 · 2022: 11 · 2021: 19 · 2020: 13 · 2019: 26 · 2018: 32 · 2017: 23 · 2016: 27 · 2015: 16 · 2014: 12 · 2013: 16 · 2012: 10
- FWCI
- 28.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- NIH Clinical Center
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- FIAU, lactic acidosis, liver failure, hepatotoxicity, chronic hepatitis B, nucleoside analogues, drug toxicity, mitochondrial damage, pancreatitis, neuropathy, myopathy, liver transplantation, drug-induced liver injury
- MeSH terms
- Acidosis, Lactic, Adult, Alanine Transaminase, Antiviral Agents, Arabinofuranosyluracil, Chronic Disease, DNA, Mitochondrial, DNA, Viral, Female, Hepatitis B, Humans, Jaundice, Liver, Male, Middle Aged, Pancreatitis, Peripheral Nervous System Diseases, Drugs, Investigational, Liver Transplantation, Liver Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
